Henry Jiang
Good morning. Thank you all for joining us today. My name is Henry Jiang. I’m with the banking team here at JPMorgan, and it’s my pleasure to be introducing the GRAIL team today. Joining me on stage and presenting today will be Bob Ragusa, CEO; and Dr. Josh Ofman, President. Just a quick note, we’ll have time for Q&A at the end. And just please wait and we’ll get you a microphone if you have any questions. But with that, I’ll pass it over to you, Bob.
Robert Ragusa
CEO & Director
Thanks, Henry. Appreciate it. So welcome, and thank you for attending this session. I’m Bob Ragusa, Chief Executive Officer at GRAIL. We’re pleased to be here to talk today about the company, the progress we’ve made as a company and the exciting year ahead. So here are our disclaimers. So today, I will share with you a business review and then Dr. Josh Ofman, who joins me up on stage here, our President, will review Galleri’s differentiation and future opportunities.
So we’re immensely proud of the progress we’ve made as a company. We launched Galleri in 2021, enabling individuals and their physicians to identify cancers before symptoms appear, often at earlier stages. These cancers typically have no recommended screenings. We see ourselves as leaders in an expansive field. We were the first to launch a multi-cancer early detection test, a brand-new testing paradigm for cancer screening and have been on the market for more than 4 years. So we demonstrated the performance of the test through a number of studies, most recently in a readout of the first 25,000 participants in
